Freelance writer/analyst for The Motley Fool, BioWorld, Nature Biotechnology, and anyone else that will let me write at the intersection of drugs and business.

Search Tweets

Twitter Feed

@BiologyFool — 3,616 followers, 1,197 tweets

May 18, 2017

Sign of the oncology times: MS Word doesn't think monotherapy is a word and suggests it be changed to immunotherapy.

May 02, 2017

$EXEL is rare example of when biotech loans work. Share price wouldn't be nearly this high if it had raised capital through 2ndary offering.

May 01, 2017

Analyst on $EXEL call asked if management wanted to comment on future profitability. A: Audible laugh from someone (CEO?) on management team

Show more